Filorexant

Filorexant

Clinical data
Other names	MK-6096; MK6096
Routes of administration	By mouth
Drug class	Orexin antagonist
ATC code	None
Pharmacokinetic data
Elimination half-life	3–6 hours
Identifiers
IUPAC name [(2R,5R)-5-{[(5-Fluoro-2-pyridinyl)oxy]methyl}-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]methanone
CAS Number	1088991-73-4 Y
PubChem CID	25128145
ChemSpider	28528372
UNII	E6BTT8VA5Z
KEGG	D10345
PDB ligand	NT5 (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID50148764
ECHA InfoCard	100.203.042
Chemical and physical data
Formula	C24H25FN4O2
Molar mass	420.488 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1CC[C@H](CN1C(=O)C2=C(C=CC(=C2)C)C3=NC=CC=N3)COC4=NC=C(C=C4)F
InChI InChI=1S/C24H25FN4O2/c1-16-4-8-20(23-26-10-3-11-27-23)21(12-16)24(30)29-14-18(6-5-17(29)2)15-31-22-9-7-19(25)13-28-22/h3-4,7-13,17-18H,5-6,14-15H2,1-2H3/t17-,18-/m1/s1 Key:NPFDWHQSDBWQLH-QZTJIDSGSA-N

Filorexant (INN, USAN; developmental code name MK-6096) is an orexin antagonist which was under development by Merck for the treatment of insomnia, depression, diabetic neuropathy, and migraine. It is a dual antagonist of the orexin OX₁ and OX₂ receptors. It has a relatively short elimination half-life of 3 to 6 hours. However, it dissociates slowly from the orexin receptors and may thereby have a longer duration. Possibly in relation to this, filorexant shows next-day somnolence similarly to suvorexant. In phase 2 clinical trials, filorexant was found to be effective in the treatment of insomnia, but was not effective in the treatment of major depressive disorder,painful diabetic neuropathy, or migraine. As of May 2015, filorexant was no longer listed on Merck's online development pipeline and hence development of the drug appears to have been discontinued. Development of filorexant may have been discontinued due to lack of differentiation from suvorexant (which was also developed by Merck).

See also

• List of investigational sleep drugs

External links

• Filorexant - AdisInsight